Treatment of autosomal dominant polycystic kidney disease;Tratamiento de la poliquistosis renal autosómica dominante

Medicina Clinica

Volumn 142, Issue 2, 2014, Pages 73-79

  Torra, Roser ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Autosomal dominant polycystic kidney disease; Pathogenesis; Treatment

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; POLYCYSTIN 1; POLYCYSTIN 2; SOMATOSTATIN DERIVATIVE; TOLVAPTAN;

CLINICAL TRIAL (TOPIC); DIALYSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MEDICAL RESEARCH; PREVALENCE; RENAL REPLACEMENT THERAPY; REVIEW;

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; PATHOGENESIS; PATOGÉNESIS; POLIQUISTOSIS RENAL AUTOSÓMICA DOMINANTE; TRATAMIENTO; TREATMENT;

ADULT; AGED; ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL REPLACEMENT THERAPY; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SOMATOSTATIN; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS; YOUNG ADULT;

EID: 84892369081     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2013.09.018     Document Type: Review

References (73)

1. C.G. Iglesias, V.E. Torres, K.P. Offord, K.E. Holley, C.M. Beard, and L.T. Kurland Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980 Am J Kidney Dis 2 1983 630 639
2. R. Torra, C. Badenas, A. Darnell, C. Nicolau, V. Volpini, and L. Revert et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2 J Am Soc Nephrol 7 1996 2142 2151
3. A.J. Collins, R.N. Foley, C. Herzog, B. Chavers, D. Gilbertson, and A. Ishani et al. US renal data system 2010 annual data report Am J Kidney Dis 57 1 Suppl 1 2011 A8, e1-526
4. P.A. Gabow Autosomal dominant polycystic kidney disease N Engl J Med 329 1993 332 342
5. A. Ozkok, T.S. Akpinar, F. Tufan, N.A. Kanitez, M. Uysal, and M. Guzel et al. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: A single center experience Clin Exp Nephrol 17 2013 345 351
6. J.J. Grantham, S. Mulamalla, and K.I. Swenson-Fields Why kidneys fail in autosomal dominant polycystic kidney disease Nat Rev Nephrol 7 2011 556 566
7. E. Cornec-Le Gall, M.P. Audrézet, J.M. Chen, M. Hourmant, M.P. Morin, and R. Perrichot et al. Type of PKD1 mutation influences renal outcome in ADPKD J Am Soc Nephrol 24 2013 1006 1013
8. N. Hateboer, M.A. Dijk, N. Bogdanova, E. Coto, A.K. Saggar-Malik, J.L. San Millan European PKD1-PKD2 Study Group Comparison of phenotypes of polycystic kidney disease types 1 and 2 Lancet 353 1999 103 107
9. The European Polycystic Kidney Disease Consortium The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16 Cell 77 1994 881 894
10. T. Mochizuki, G. Wu, T. Hayashi, S.L. Xenophontos, B. Veldhuisen, and J.J. Saris et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein Science 272 1996 1339 1342
11. F. Hildebrandt, T. Benzing, and N. Katsanis Ciliopathies N Engl J Med 364 2011 1533 1543
12. V.E. Torres, and P.C. Harris Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases Nat Clin Pract Nephrol 2 2006 40 55
13. K. Hanaoka, and W.B. Guggino cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells J Am Soc Nephrol 11 2000 1179 1187
14. K. Hanaoka, O. Devuyst, E.M. Schwiebert, P.D. Wilson, and W.B. Guggino A role for CFTR in human autosomal dominant polycystic kidney disease Am J Physiol 270 1996 C389 C399
15. X. Wang, Y. Wu, C.J. Ward, P.C. Harris, and V.E. Torres Vasopressin directly regulates cyst growth in polycystic kidney disease J Am Soc Nephrol 19 2008 102 108
16. J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, and N. Brown et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc Natl Acad Sci U S A 103 2006 5466 5471
17. T. Weimbs Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair? Cell Cycle 5 2006 2425 2429
18. O.Z. Dalgaard Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families Acta Med Scand Suppl 328 1957 1 255
19. G.M. Brosnahan Volume progression in polycystic kidney disease N Engl J Med 355 2006 733 734
20. A.B. Chapman, J.E. Bost, V.E. Torres, L. Guay-Woodford, K.T. Bae, and D. Landsittel et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 7 2012 479 486
21. A.D. Kistler, D. Poster, F. Krauer, D. Weishaupt, S. Raina, and O. Senn et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months Kidney Int 75 2009 235 241
22. V.E. Torres, X. Wang, Q. Qian, S. Somlo, P.C. Harris, and V.H. Gattone Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease Nat Med 10 2004 363 364
23. X. Wang, V. Gattone, P.C. Harris, and V.E. Torres Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat J Am Soc Nephrol 16 2005 846 851
24. R. Kelsey Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results Nat Rev Nephrol 9 2013 1
25. V.E. Torres Water for ADPKD? Probably, yes J Am Soc Nephrol 17 2006 2089 2091
26. J.H. Lewis, M. Ahmed, A. Shobassy, and C. Palese Drug-induced liver disease Curr Opin Gastroenterol 22 2006 223 233
27. S. Nagao, K. Nishii, M. Katsuyama, H. Kurahashi, T. Marunouchi, and H. Takahashi et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat J Am Soc Nephrol 17 2006 2220 2227
28. C.J. Wang, C. Creed, F.T. Winklhofer, and J.J. Grantham Water prescription in autosomal dominant polycystic kidney disease: A pilot study Clin J Am Soc Nephrol 6 2011 192 197
29. P. Ruggenenti, A. Remuzzi, P. Ondei, G. Fasolini, L. Antiga, and B. Ene-Iordache et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 2005 206 216
30. M. Chrispijn, F. Nevens, T.J. Gevers, R. Vanslembrouck, M.G. van Oijen, and W. Coudyzer et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2012 266 274
31. M.C. Hogan, T.V. Masyuk, L. Page, D.R. Holmes III, X. Li, and E.J. Bergstralh et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years Nephrol Dial Transplant 27 2012 3532 3539
32. A. Caroli, L. Antiga, M. Cafaro, G. Fasolini, A. Remuzzi, and G. Remuzzi et al. Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 2010 783 789
33. M. Chrispijn, T.J. Gevers, J.C. Hol, R. Monshouwer, H.M. Dekker, and J.P. Drenth Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial J Hepatol 59 2013 153 159
34. T.V. Masyuk, B.N. Radtke, A.J. Stroope, J.M. Banales, S.A. Gradilone, and B. Huang et al. Pasireotide is more effective than octreotide in reducing hepato-renal cystogenesis in rodents with polycystic kidney and liver diseases Hepatology 58 2013 409 421
35. V.E. Torres, A. Boletta, A. Chapman, V. Gattone, Y. Pei, and Q. Qian et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases Clin J Am Soc Nephrol 5 2010 1312 1329
36. A.L. Serra, D. Poster, A.D. Kistler, F. Krauer, S. Raina, and J. Young et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease N Engl J Med 363 2010 820 829
37. G. Walz, K. Budde, M. Mannaa, J. Nürnberger, C. Wanner, and C. Sommerer et al. Everolimus in patients with autosomal dominant polycystic kidney disease N Engl J Med 363 2010 830 840
38. N. Perico, L. Antiga, A. Caroli, P. Ruggenenti, G. Fasolini, and M. Cafaro et al. Sirolimus therapy to halt the progression of ADPKD J Am Soc Nephrol 21 2010 1031 1040
39. M.J. Jardine, T. Liyanage, E. Buxton, and V. Perkovic mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): The question remains open Nephrol Dial Transplant 28 2013 242 244
40. P.A. Gabow, A.M. Johnson, W.D. Kaehny, W.J. Kimberling, D.C. Lezotte, and I.T. Duley et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease Kidney Int 41 1992 1311 1319
41. M. Loghman-Adham, C.E. Soto, T. Inagami, and L. Cassis The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease Am J Physiol Renal Physiol 287 2004 F775 F788
42. R.W. Schrier, K.K. McFann, and A.M. Johnson Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease Kidney Int 63 2003 678 685
43. B. Orskov, V. Rømming Sørensen, B. Feldt-Rasmussen, and S. Strandgaard Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark Clin J Am Soc Nephrol 5 2010 2034 2039
44. C. Patch, J. Charlton, P.J. Roderick, and M.C. Gulliford Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study Am J Kidney Dis 57 2011 856 862
45. A.B. Chapman, V.E. Torres, R.D. Perrone, T.I. Steinman, K.T. Bae, and J.P. Miller et al. The HALT polycystic kidney disease trials: Design and implementation Clin J Am Soc Nephrol 5 2010 102 109
46. H.H. Parving, B.M. Brenner, J.J. McMurray, D. de Zeeuw, S.M. Haffner, S.D. Solomon ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
47. R. Backenroth, and M.M. Popovtzer Does type 2 diabetes mellitus delay renal failure in autosomal dominant polycystic kidney disease? Ren Fail 24 2002 803 813
48. J.D. Goldman-Levine Beyond metformin: Initiating combination therapy in patients with type 2 diabetes mellitus Pharmacotherapy 31 12 Suppl 2011 44S 53S
49. B. Reed, I. Helal, K. McFann, W. Wang, X.D. Yan, and R.W. Schrier The impact of type ii diabetes mellitus in patients with autosomal dominant polycystic kidney disease Nephrol Dial Transplant 27 2012 2862 2865
50. W.E. Sweeney Jr., R.O. von Vigier, P. Frost, and E.D. Avner Src inhibition ameliorates polycystic kidney disease J Am Soc Nephrol 19 2008 1331 1341
51. J. Elliott, N.N. Zheleznova, and P.K. Wilson c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation Am J Physiol Cell Physiol 301 2011 C522 C529
52. S.J. Leuenroth, D. Okuhara, J.D. Shotwell, G.S. Markowitz, Z. Yu, and S. Somlo et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease Proc Natl Acad Sci U S A 104 2007 4389 4394
53. S.J. Leuenroth, N. Bencivenga, H. Chahboune, F. Hyder, and C.M. Crews Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD Nephrol Dial Transplant 25 2010 2187 2194
54. C. Spirli, C.M. Morell, L. Locatelli, S. Okolicsanyi, C. Ferrero, and A.K. Kim et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib Hepatology 56 2012 2363 2374
55. B. Buchholz, B. Klanke, G. Schley, G. Bollag, J. Tsai, and S. Kroening et al. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis Nephrol Dial Transplant 26 2011 3458 3465
56. N.O. Bukanov, L.A. Smith, K.W. Klinger, S.R. Ledbetter, and O. Ibraghimov-Beskrovnaya Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine Nature 444 2006 949 952
57. N.O. Bukanov, S.E. Moreno, T.A. Natoli, K.A. Rogers, L.A. Smith, and S.R. Ledbetter et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD Cell Cycle 11 2012 4040 4046
58. H. Li, W. Yang, F. Mendes, M.D. Amaral, and D.N. Sheppard Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth Am J Physiol Renal Physiol 303 2012 F1176 F1186
59. B. Yang, N.D. Sonawane, D. Zhao, S. Somlo, and A.S. Verkman Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease J Am Soc Nephrol 19 2008 1300 1310
60. C. Huang, and R.T. Miller Regulation of renal ion transport by the calcium-sensing receptor: An update Curr Opin Nephrol Hypertens 16 2007 437 443
61. V.H. Gattone, N.X. Chen, R.M. Sinders, M.F. Seifert, D. Duan, and D. Martin et al. Calcimimetic inhibits late-stage cyst growth in ADPKD J Am Soc Nephrol 20 2009 1527 1532
62. X. Wang, P.C. Harris, S. Somlo, D. Batlle, and V.E. Torres Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease Nephrol Dial Transplant 24 2009 526 534
63. C. Xu, B.E. Shmukler, K. Nishimura, E. Kaczmarek, S. Rossetti, and P.C. Harris et al. Attenuated, flow-induced ATP release contributes to absence of flow-sensitive, purinergic Cai2+ signaling in human ADPKD cyst epithelial cells Am J Physiol Renal Physiol 296 2009 F1464 F1476
64. M.Y. Chang, J.K. Lu, Y.C. Tian, Y.C. Chen, C.C. Hung, and Y.H. Huang et al. Inhibition of the P2X7 receptor reduces cystogenesis in PKD J Am Soc Nephrol 2 2011 1696 1706
65. A. Takakura, E.A. Nelson, N. Haque, B.D. Humphreys, K. Zandi-Nejad, and D.A. Frank et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways Hum Mol Genet 20 2011 4143 4154
66. J.J. Talbot, J.M. Shillingford, S. Vasanth, N. Doerr, S. Mukherjee, and M.T. Kinter et al. Polycystin-1 regulates STAT activity by a dual mechanism Proc Natl Acad Sci U S A 108 2011 7985 7990
67. E.E. Olsan, S. Mukherjee, B. Wulkersdorfer, J.M. Shillingford, A.J. Giovannone, and G. Todorov et al. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease Proc Natl Acad Sci U S A 108 2011 18067 18072
68. T.A. Natoli, L.A. Smith, K.A. Rogers, B. Wang, S. Komarnitsky, and Y. Budman et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models Nat Med 16 2010 788 792
69. W.N. Leonhard, A. van der Wal, Z. Novalic, S.J. Kunnen, R.T. Gansevoort, and M.H. Breuning et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model Am J Physiol Renal Physiol 300 2011 F1193 F1202
70. J. Gao, H. Zhou, T. Lei, L. Zhou, W. Li, and X. Li et al. Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways Eur J Pharmacol 654 2011 92 99
71. S. Nagao, and T. Yamaguchi PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders Curr Mol Pharmacol 5 2012 292 300
72. S. Muto, A. Aiba, Y. Saito, K. Nakao, K. Nakamura, and K. Tomita et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant Hum Mol Genet 11 2002 1731 1742
73. A. Caroli, L. Antiga, S. Conti, A. Sonzogni, G. Fasolini, and P. Ondei et al. Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients Am J Pathol 17 2011 619 627